SK Biopharmaceuticals Co Ltd
KRX:326030

Watchlist Manager
SK Biopharmaceuticals Co Ltd Logo
SK Biopharmaceuticals Co Ltd
KRX:326030
Watchlist
Price: 102 400 KRW -1.54%
Market Cap: 8T KRW
Have any thoughts about
SK Biopharmaceuticals Co Ltd?
Write Note

SK Biopharmaceuticals Co Ltd
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

SK Biopharmaceuticals Co Ltd
Additional Paid In Capital Peer Comparison

Comparables:
000100
008930
128940
S
000250
C
068760

Competitive Additional Paid In Capital Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
SK Biopharmaceuticals Co Ltd
KRX:326030
Additional Paid In Capital
â‚©1.1T
CAGR 3-Years
0%
CAGR 5-Years
19%
CAGR 10-Years
N/A
Yuhan Corp
KRX:000100
Additional Paid In Capital
-â‚©117.3B
CAGR 3-Years
-21%
CAGR 5-Years
-16%
CAGR 10-Years
-18%
Hanmi Science Co Ltd
KRX:008930
Additional Paid In Capital
â‚©227B
CAGR 3-Years
-7%
CAGR 5-Years
-5%
CAGR 10-Years
0%
Hanmi Pharm Co Ltd
KRX:128940
Additional Paid In Capital
â‚©368B
CAGR 3-Years
-1%
CAGR 5-Years
-1%
CAGR 10-Years
-1%
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Additional Paid In Capital
â‚©99.7B
CAGR 3-Years
29%
CAGR 5-Years
43%
CAGR 10-Years
23%
C
Celltrion Pharm Inc
KOSDAQ:068760
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is SK Biopharmaceuticals Co Ltd's Additional Paid In Capital?
Additional Paid In Capital
1.1T KRW

Based on the financial report for Dec 31, 2023, SK Biopharmaceuticals Co Ltd's Additional Paid In Capital amounts to 1.1T KRW.

What is SK Biopharmaceuticals Co Ltd's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
19%

Over the last year, the Additional Paid In Capital growth was 0%.

Back to Top